The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Paramount Skydance raised its full-year 2026 adjusted EBITDA outlook during its second-quarter earnings report. The company reaffirmed its commitment to the merger with Warner Bros. Discovery despite ongoing legal and regulatory challenges. Additionally, several other firms reported financial results, with Iovance Biotherapeutics achieving record revenue driven by Amtagvi sales. Ocugen also received FDA clearance for a Phase 3 trial and secured $130 million in financing, extending its cash runway into 2028.